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Purpose
Malignant peripheral nerve sheath tumors (MPNSTs) are a rare subtype of sarcoma that
occur spontaneously or in association with neurofibromatosis type 1 (NF-1). This study
aimed to clinically differentiate these types of MPNSTs.
Materials and Methods
The study reviewed 95 patients diagnosed with and treated for MPNST at Yonsei University
Health System, Seoul, Korea over a 27-year period. The clinical characteristics, prognostic
factors, and treatment outcomes of sporadic MPNST (sMPNST) and NF-1 associated MPNST
(NF-MPNST) cases were compared.
Results
Patients with NF-MPNST had a significantly lower median age (32 years vs. 45 years for
sMPNST, p=0.012), significantly larger median tumor size (8.2 cm vs. 5.0 cm for sMPNST,
p < 0.001), and significantly larger numbers of imaging studies and surgeries (p=0.004
and p < 0.001, respectively). The 10-year overall survival (OS) rate of the patients with
MPNST was 52±6%. Among the patients with localized MPNST, patients with NF-MPNST
had a significantly lower 10-year OS rate (45±11% vs. 60±8% for sMPNST, p=0.046). Uni-
variate analysis revealed the resection margin, pathology grade, and metastasis to be sig-
nificant factors affecting the OS (p=0.001, p=0.020, and p < 0.001, respectively).
Multivariate analysis of the patients with localized MPNST identified R2 resection and G1
as significant prognostic factors for OS. 
Conclusion
NF-MPNST has different clinical features from sMPNST and requires more careful manage-
ment. Further study will be needed to develop specific management plans for NF-MPNST.
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Introduction
Malignant peripheral nerve sheath tumor (MPNST) is a
type of soft tissue sarcoma that originates from the peripheral
nerve sheath. These tumors account for 5%-10% of all soft tis-
sue tumors, but their occurrence is rare in the general popu-
lation with an estimated annual incidence of 1/1,000,000 
individuals [1-3]. MPNST is frequently associated with neu-
rofibromatosis, and has an incidence of 2%-5% among 
patients with neurofibromatosis type 1 (NF-1); this incidence
is very high relative to that of the general population [2].
MPNST is considered aggressive and is associated with a low
survival rate (34%-52%) [4]. The prognosis of MPNST is 
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associated with the tumor size and location, resection mar-
gin, adjuvant chemotherapy, distant metastasis, stage, and
site [5-7].
NF-1 is an autosomal hereditary syndrome characterized
by symptoms and signs, such as neurofibromas, café-au-lait
spots, osseous lesions, optic pathway glioma, axillary or 
inguinal freckling, and Lisch nodules, with a global incidence
of 1/2,500-1/3,000 individuals [8,9]. Throughout their lives,
patients with NF-1 frequently develop benign and malignant
tumors consequent to the loss of the tumor suppressive 
activity of NF1 [8]. The descendants of patients with NF-1 are
born with a systemic heterozygous NF1 mutation; however,
a mutation of the second normal copy is required for the for-
mation of NF1-related tumors [10]. Patients with NF-1 carry
an approximately 2.5- to 4-fold higher risk of malignancy rel-
ative to the general population, as well as the risk of optic
glioma and soft tissue sarcoma, which have been reported to
occur in 15%-20 % and 4%-25% of patients, respectively [8]. 
The prognostic role of a patient’s NF-1 status with regard
to the MPNST treatment has been studied because the 
genetic backgrounds underlying sporadic MPNST (sMP-
NST) and MPNST arising in patients with NF-1 (NF-1 asso-
ciated MPNST, NF-MPNST) differ, and the clinical mani-
festations of NF-1 frequently include multiple benign and
malignant tumors [6,11,12]. On the other hand, the differ-
ences in survival associated with these different subtypes is
controversial [6,11-16]. Although many researchers have 
reported the characteristic features of NF-MPNSTs, there are
no standard management guidelines for this subtype. The
present study evaluated the clinical differences between the
two subtypes of MPNST to further the development of spe-
cific diagnostic and treatment strategies for NF-MPNST.
Materials and Methods
1. Patient population
A total of 95 patients diagnosed with and treated for
MPNST at the Yonsei Cancer Center, Yonsei University
Health System, Seoul, Korea from 1988 to 2015 were enrolled
in this study. The clinical data were collected via retrospec-
tive chart review. A clinical diagnosis of NF-1 was confirmed
by the presence of one of the following criteria: confirmed
NF1 mutation and associated symptoms, or ! 2 clinical man-
ifestations that met the National Institutes of Health (NIH)
consensus criteria [3,9]. The direct polymerase chain reaction
sequencing method of the patient DNA isolated from a blood
sample was used for a genetic NF1 test. Among the 33 
patients, 32 met the clinical diagnosis criteria fully. Among
them, an additional genetic test was performed for sixpa-
tients. For only one patient who did not meet the clinical 
diagnostic criteria, the genetic test was used to confirm 
NF-1. NF-MPNST was defined as MPNST that occurred in a
patient diagnosed with NF-1, and sMPNST was defined as
MPNST arising in a patient without NF-1. This study was 
approved by the Institutional Review Board of Severance
Hospital, Yonsei University Health System (No. 4-2016-
0401).
2. Treatment
Surgery was generally performed with curative intent. Pal-
liative surgery was performed to relieve the symptoms
caused by the tumor. A biopsy alone was performed in two
cases involving unresectable lesions. Radiotherapy was gen-
erally administered to patients with positive tumor margins
after surgery or to reduce symptoms, such as pain or other
neurologic signs. Chemotherapy was generally administered
for metastatic MPNST or recurrent disease. First-line adju-
vant treatments for localized MPNST were evaluated as
treatment patterns.
3. Clinical data
The pathologic diagnoses of MPNST were initially made
but were reviewed by the institutional pathologist at the time
of the study in accordance with the Fédération Nationale des
Centres de Lutte Contre le Cancer (FNCLCC) pathologic
grading system [17]. The FNCLCC system considered the
cellularity, nuclear pleomorphism, anaplasia, mitotic rate,
necrosis, and microvascular proliferation [17]. For 15 of the
95 patients, the grades could not be defined either because
these patients had been referred from other institutions
(n=10) or tissues were unavailable because the diagnoses had
been made at least 20 years earlier (n=5).
Information on the chemotherapeutic regimens was col-
lected from the medical records. Data regarding the tumor
size and depth, lymph node involvement, and distant metas-
tases were collected from imaging studies, which included
computed tomography, magnetic resonance imaging, ultra-
sonography, and positron emission tomography. This study
evaluated the total number of imaging studies or operations
including biopsies, which are defined as the sum of the num-
ber of imaging studies or operations performed between the
time of diagnosis and the last follow-up. Disease progression
was defined as tumor growth after surgical intervention, 
radiotherapy, or chemotherapy, based on imaging studies.
Staging information according to the seventh American Joint
Committee on Cancer (AJCC) staging system was obtained
from the surgical records [18]. The margin status was defined
as follows: R0, microscopically negative margins (tumor-free
VOLUME 49 NUMBER 3 JULY 2017  719
margin > 2 mm); R1, macroscopically negative margins with
microscopically positive margins; or R2, macroscopically
positive margins. 
4. Statistics
The overall survival (OS) was calculated as the interval
from the date of diagnosis to the date of death from any
cause or the last follow-up. OS was calculated using the num-
ber of deaths prior to April 30, 2016. A chi-square test or
Fisher exact test was used to analyze the categorical vari-
ables, and a Student's t test or Mann-Whitney test and an
analysis of variance (ANOVA) or the Kruskal-Wallis test
were used to analyze the continuous variables. The Kaplan-
Meier method was used for survival analyses, and the results
were compared using a log-rank test. A Cox proportional
In Kyung Hwang, Outcome of NF-1–Associated MPNST
Values are presented as number (%). NF-1, neurofibromatosis type 1; N/A, not acquired; MPNST, malignant peripheral nerve
sheath tumors. a)Linear by linear association, b)R0/R1/2, resection margin, see details in Materials and Methods section.
Table 1. Demographic characteristics of patients with malignant peripheral nerve sheath tumors
Parameter Total (n=95) Sporadic (n=62) NF-1 (n=33) p-value
Age at diagnosis (yr) 40.4 (28.3-54.0) 45.3 (29.0-59.3) 31.9 (28.3-42.9) 0.014
Age at expire (yr) 43.1 (28.9-58.5) 51.8 (31.4-61.1) 36.1 (28.9-48.9) 0.201
Sex
Male 50 (53) 33 (53) 17 (52) 0.874
Female 45 (47) 29 (47) 16 (49)
Location
Trunk 34 (36) 19 (31) 15 (46) 0.325
Extermity 45 (47) 31 (50) 14 (42)
Head and neck 16 (17) 12 (19) 4 (12)
Tumor size (cm)
< 5 39 (41) 35 (57) 4 (12) < 0.001
! 5 54 (57) 26 (42) 28 (85)
N/A 2 (2) 1 (2) 1 (3)
Depth
Superficial tumor 11 (12) 7 (11) 4 (12) 0.904
Deep tumor 84 (88) 55 (89) 29 (88)
Multiple lesion
Metachronous metastasis 7 (7) 3 (5) 4 (12) 0.387
Multiple primary 3 (3) 2 (3) 1 (3)
Histologic grade (n=80)
1 23 (29) 16 (32) 7 (23) 0.302a)
2 35 (44) 22 (44) 13 (43)
3 22 (27) 12 (24) 10 (34)
Stage
IA 27 (28) 24 (39) 3 (9) 0.002a)
IB 21 (22) 10 (16) 11 (33)
IIA 8 (8) 8 (13) 0 (0)
IIB 18 (19) 9 (15) 9 (27)
III 12 (13) 5 (8) 7 (22)
IV 9 (10) 6 (10) 3 (9)
Metastasis
Yes 9 (10) 6 (10) 3 (9) 0.926
No 86 (90) 56 (90) 30 (91)
Margin status (in localized MPNST)b)
R0 45 (52) 35 (63) 10 (33) 0.035 
R1 18 (21) 9 (16) 9 (30)
R2 23 (27) 12 (21) 11 (37)
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Localized
  sMPNST (n=56)
  NF-MPNST (n=30)
Neoadjuvant
  sMPNST (n=5, 8.9%)
  NF-MPNST (n=2, 6.7%)
R0
sMPNST (n=4), NF-MPNST (n=1)
R1
sMPNST (n=1), NF-MPNST (n=1)
None
  sMPNST (n=18, 60.0%)
  NF-MPNST (n=4, 44.4%)
Chemo
  sMPNST (n=3, 10.0%)
  NF-MPNST (n=0)
RT
  sMPNST (n=9, 30.0%)
  NF-MPNST (n=4, 44.4%)
Both
  sMPNST (n=0)
  NF-MPNST (n=1, 11,1%)
Tx refusal (n=1)
F/U loss (n=3)
F/U loss (n=2)
Progressed before further treatment (n=1)
Tx refusal (n=2)
NED
  sMPNST (n=16)
  NF-MPNST (n=7)
Another primary
  sMPNST (n=0)
  NF-MPNST (n=0)
Local recur
  sMPNST (n=7)
  NF-MPNST (n=1)
Distant recur
  sMPNST (n=5)
  NF-MPNST (n=1)
R0
  sMPNST (n=31, 53.6%)
  NF-MPNST (n=9, 30.0%)
None
  sMPNST (n=4, 50.0%)
  NF-MPNST (n=2, 25.0%)
Chemo
  sMPNST (n=0)
  NF-MPNST (n=0)
RT
  sMPNST (n=3, 37.5%)
  NF-MPNST (n=6, 75.0%)
Both
  sMPNST (n=1, 12.5%)
  NF-MPNST (n=0)
R1
  sMPNST (n=8, 14.3%)
  NF-MPNST (n=8, 26.7%)
None
  sMPNST (n=0)
  NF-MPNST (n=1, 10.0%)
Chemo
  sMPNST (n=1, 9.1%)
  NF-MPNST (n=3, 30.0%)
RT
  sMPNST (n=9, 75.0%)
  NF-MPNST (n=3, 30.0%)
Both
  sMPNST (n=1, 9.1%)
  NF-MPNST (n=3. 30.0%)
R2
  sMPNST (n=12, 23.2%)
  NF-MPNST (n=11, 36.7%)
NED
  sMPNST (n=2)
  NF-MPNST (n=1)
Another primary
  sMPNST (n=0)
  NF-MPNST (n=1)
Local recur
  sMPNST (n=0)
  NF-MPNST (n=0)
Distant recur
  sMPNST (n=3)
  NF-MPNST (n=0)
NED
  sMPNST (n=2)
  NF-MPNST (n=1)
Another primary
  sMPNST (n=0)
  NF-MPNST (n=1)
Local recur
  sMPNST (n=3)
  NF-MPNST (n=2)
Distant recur
  sMPNST (n=3)
  NF-MPNST (n=4)
NED
  sMPNST (n=5)
  NF-MPNST (n=4)
Another primary
  sMPNST (n=0)
  NF-MPNST (n=0)
Local recur
  sMPNST (n=3)
  NF-MPNST (n=4)
Distant recur
  sMPNST (n=3)
  NF-MPNST (n=1)
Fig. 1.  Scheme of first-line treatment modalities. sMPNST, sporadic malignant peripheral nerve sheath tumors; NF-MPNST,
malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1; Chemo, chemotherapy; RT, radiother-
apy; Both, chemotherapy and radiotherapy; NED, no evidence of disease; R0/R1/2, resection margin, see details in Materials
and Methods section; Tx, treatment; F/U, follow-up.
VOLUME 49 NUMBER 3 JULY 2017  721
hazard regression model was used for multivariate data
analysis and included the factors identified as significant in
univariate analysis. Age was also included because this fac-
tor was considered clinically meaningful with respect to the
treatment tolerability and hereditary cancer syndrome. SPSS
ver. 20 for Windows (IBM Corp., Armonk, NY) was used for
the statistical analysis of each outcome measure.
Results
1. Clinical characteristics
The overall median age was 40.4 years (interquartile range,
28.3 to 54.0 years; range, 8.3 to 80.4 years) (Table 1). In par-
ticular, the 33 patients (35%) with NF-MPNST had a signifi-
cantly lower median age (31.9 years vs. 45.3 years for
sMPNST, p=0.012). Forty-five patients (47%) in the overall
group were female, and no significant sex-related difference
was observed between the patients with sMPNST and 
NF-MPNST. 
Overall, the tumors presented most frequently in the 
extremities (n=45, 47%), followed by the trunk (n=34, 35%)
and head and neck (n=16, 17%). Among patients with 
NF-MPNST, the trunk was the most common tumor site
(n=15, 46%), whereas the extremities were the most common
sites among patients with sMPNST (n=31, 50%). On the other
hand, these inter-group differences in MPNST sites were not
significant (p=0.325). The median size of the primary 
NF-MPNSTs was greater than that of the sMPNSTs (8.2 cm
vs. 5.0 cm, p < 0.001), and the proportion of large primary 
tumors (size > 5 cm) was significantly higher among the 
patients with NF-MPNST than those with sMPNST (28 [85%]
vs. 26 [42%], p < 0.001). 
Generally, most tumors were located deep beneath the fas-
cia (88% overall; 89% for sMPNST vs. 88% for NF-MPNST,
p=0.904). The histologic grade was similar in the two groups
(p=0.302, linear by linear association). In contrast, the 
NF-MPNST patients were significantly more likely to have a
higher tumor stage (p=0.002, linear by linear association)
(Table 1). Among the cases of localized MPNST, the fre-
quency of patients with NF-MPNST who had positive tumor
margins comprised the majority of such patients and was sig-
nificantly higher than the frequency among patients with
sMPNST (66.7% vs. 47.6%, p=0.035). Similar frequencies of
metastases were observed in both groups (6 [10%] vs. 3 [9%],
p=0.926). 
2. Management patterns
Overall, 93 patients (98%) underwent primary surgery.
Only two patients (2%) underwent a biopsy alone. In addi-
tion, 46 patients (48%) received radiotherapy, and 27 (28.4%,
27/95) received chemotherapy; of these, 16 had sMPNST.
Seven patients (28%, 7/25) received neoadjuvant chemother-
apy. Anthracyclines (15%), ifosfamide (27%), cisplatin (17%),
and etoposide (5%) were the most commonly used che-
motherapeutic agents, and the most common regimen was
anthracycline+ifosfamide (41%, 11/27), followed by ifos-
famide+cisplatin+etoposide (26%, 7/27). Only two patients
were treated with anthracycline+ifosfamide+cisplatin (7%,
2/27), and one patient used anthracycline+cisplatin and ifos-
famide+cisplatin (S1 Table).
The first-line treatment schemes administered to patients
with localized sMPNST and NF-MPNST were compared
(Fig. 1). In the R0 group, 60% (18/30) of patients with sMP-
NST received no further therapy, whereas 56% (5/9) with
NF-MPNST received adjuvant treatments (p=0.202). In the
R1 group, 50% (4/8) of patients with sMPNST received no
treatment, whereas 75% (6.8) of those with NF-MPNST 
received further adjuvant treatments (p=0.315). In the R2
group, 9% (1/11) of patients with sMPNST and 30% (3/10)
with NF-MPNST received chemotherapy and radiotherapy
both as the adjuvant treatment (p=0.181). When the analysis
was limited to localized MPNST in total, 76 patients (49 sMP-
NSTs and 27 NF-MPNSTs) underwent a primary resection.
Among them, 38% (n=29) received no adjuvant treatment,
54% (n=41) received chemotherapy or radiotherapy, and 8%
(n=6) received both treatments. A total of 45% (22/49) of 
patients with sMPNST received no further treatment,
whereas 74% (20/27) of those with NF-MPNST received 
adjuvant treatment, including chemotherapy, radiotherapy,
or both (p=0.04999). In addition, the NF-1 patients under-
went a higher median annual number of imaging studies
(7.54 vs. 3.67 for sMPNST, p=0.004) and operations, includ-
ing biopsy (2.45 vs. 0.70, p < 0.001) during the follow-up 
period (S2 Table).
3. Survival outcomes
The 10-year OS rate of the entire study cohort was 52±6%
(Fig. 2). In particular, although the 10-year OS rate was lower
among patients with NF-MPNST than among those with
sMPNST, this difference was not significant (44±11% vs.
56±7%, p=0.084) (S3 Fig.). On the other hand, among patients
with localized MPNST, those with NF-MPNST had a signif-
icantly lower 10-year survival rate (45±11% for NF-MPNST
vs. 60±8% for sMPNST, p=0.046) (Fig. 3A). In contrast, 
patients with metastasis had similar survival outcomes, 
regardless of the subtype (5-year OS, 33±27% for NF-MPNST
In Kyung Hwang, Outcome of NF-1–Associated MPNST
vs. 17±15% for sMPNST, p=0.875) (Fig. 3B). 
Patients with R0 margins had a significantly higher 10-year
OS rate than the patients with other margin statuses (65±9%
for R0; 41±7% for R1 or R2; p=0.001) (Fig. 4A). The patients
with pathologic G1 disease had a better 10-year OS rate than
those in the other staging groups (G1 vs. G2 vs. G3 vs. N/A;
82±9% vs. 31±12% vs. 44±12% vs. 51±13%, respectively,
p=0.020) (Fig. 4B). Metastasis at the time of diagnosis was 
associated with a poorer prognosis (5-year OS, 55±6% for 
localized MPNST vs. 22±14% for MPNST with metastasis, 
p < 0.001) (Fig. 4C). No survival difference was observed
with respect to the use of a doublet vs. triplet regimen
(50±14% vs. 53±15%, p=0.738) or to the tumor location and
size ! 5 cm (p=0.264 and p=0.113, respectively; data not
shown). 
4. Multivariate analysis of clinical risk factors affecting OS
in localized MPNSTs
Because NF-1 was identified as a significant prognostic fac-
tor for OS among patients with localized MPNSTs in the uni-
variate analysis, multivariate analysis was performed to
confirm the risk factors for OS. The R2 status was confirmed
to be a significant risk factor for OS (hazard ratio, 2.61; 95%
confidence interval [CI], 1.03 to 6.61), and histologic G1 dis-
ease was identified to be more favorable for OS compared to
G3 disease (odds ratio [OR], 0.18; 95% CI, 0.05 to 0.71). On
the other hand, the NF-1 status was found to be an insignif-
icant prognostic factor for OS (OR, 1.18; 95% CI, 0.48 to 2.90).
Age > 45 years and a positive resection margin were not
identified as significant prognostic factors (Table 2).
Discussion
The identified frequency of NF-MPNSTs in this study was
35%; previous studies have reported a frequencies of 20% to
70% [7,16,19-21]. NF-MPNST was found to be related to a
Cancer Res Treat. 2017;49(3):717-726
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Fig. 3.  Overall survival according to neurofibromatosis type 1 (NF-1) status. (A) Overall survival associated with non-
metastatic malignant peripheral nerve sheath tumors. (B) Overall survival associated with metastatic malignant peripheral
nerve sheath tumors. 
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Fig. 2.  Overall survival of patients with malignant periph-
eral nerve sheath tumors.
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younger age of onset, greater tumor size, and higher disease
stage; these findings are in line with those of many previ-
ously reports [5,6,12,16,20,21]. Consistent with previous 
reports, a lower frequency of R0 resection was observed
among patients with NF-MPNST compared to those with
sMPNST [19,21,22]. Overall, these findings might affect the
survival of patients with NF-MPNST. 
In previous reports, the 10-year survival rates of MPNST
ranged from 30% to 60% [6,11,12,21,23]. The observed 
10-year OS rate of 52±6% was consistent with previous 
reports. The survival differences of patients with NF-MPNST
and those with sMPNST are controversial. In the present
study, the survival of patients with NF-MPNST was inferior
to that of patients with sMPNST when cases of localized dis-
ease were analyzed, even though this was not confirmed in
multivariate analysis. Many studies reported poorer survival
among patients with NF-MPNST [5,11,20]; in contrast, others
have reported no significant difference in survival between
the two MPNST groups [7,10,12,16]. To the best of the 
authors’ knowledge, no previous report has demonstrated a
better survival among patients with NF-MPNST. In other
words, the survival of patients with NF-MPNST is equivalent
to or poorer than that of patients with sMPNST. 
Given the rarity of MPNST, few studies have been able to
analyze more than 100 MPNSTs from a single institution, and
existing large studies have tended to report lower survival
among patients with NF-MPNST [5,6,11,23-25]. This article
is similar to previous reports that also demonstrated a sur-
vival difference in univariate analysis but failed to confirm
the significance of this difference in multivariate analysis
[6,15]. This pattern might be due to confounding factors, such
as poor prognostic factors associated specifically with 
NF-MPNST [5,6,15]. In particular, articles published before
2000 tended to report poorer survival outcomes among 
patients with NF-MPNST. Since 2000, however, the differ-
ences in survival between the two subtypes have narrowed
[5,12,24,25]. The treatment protocols used prior to 2000 were
different from the current treatment trends, which tended 
toward more intensive treatment. Over time, previous arti-
cles may represent the natural history of NF-MPNST, as well
as the essential differences related to the genetic background
and clinical characteristics. Despite the reduction or absence
of survival differences in recent articles, the considerable het-
erogeneity among the study cohorts prevents a direct com-
parison [12,21]. 
As in many previous articles, metastasis was identified as
a poor prognostic factor for both NF-MPNST and sMPNST
[5,6,11]. Porter et al. [11] reported significant survival differ-
ences between the subtypes in an analyses of both localized
and total MPNSTs, whereas Anghileri et al. [15] reported a
survival difference among localized MPNSTs. Carli et al. [5]
reported a survival difference between the subtypes, even in
Fig. 4.  Overall survival according to the risk factors. (A)
Overall survival associated with the margin status (posi-
tive vs. negative). (B) Overall survival associated with the
pathologic grade (not acquired [N/A] vs. G1 vs. G2 vs.
G3). (C) Overall survival associated with the metastatic
status (localized vs. metastasis).
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a total MPNST group (including localized and metastatic dis-
ease) and attributed this difference to the more frequent 
incidence of metastatic disease among patients with NF-1. In
the present cohort, a significant survival difference was 
observed between NF-MPNST and sMPNST among local-
ized MPNSTs, whereas only a non-specific tendency was 
observed in the total group. In contrast to Carli et al. [5], the
frequency of metastasis was similar in patients with NF-
MPN-ST and sMPNST. Hence, the survival difference 
between these subgroups in the total cohort might not have
been evident. In addition, as metastasis might be a stronger
prognostic factor than NF-1, the survival difference between
the subtypes might be more evident when metastatic disease
is excluded.
Patients with NF-1 tend to develop numerous benign 
tumors, including preexisting neurofibromas. Therefore, it is
challenging for clinicians to differentiate newly developed
malignancies from underlying benign tumors associated
with NF-1 [8,10,12,20]. The life time risk of MPNST in NF-1
patients is high (8%-13%) [20]. This unique finding and the
clinical characteristics associated with NF-MPNST affect the
disease management patterns, including treatments and can-
cer surveillance. Regarding the treatment patterns, patients
with NF-MPNST also tended to receive adjuvant treatments
more frequently than patients with sMPNST. NF-MPNST is
associated with a low likelihood of a R0 resection and a
higher probability of a large tumor size, and clinicians tend
to choose additional treatments to avoid the risk of recur-
rence even if a curative resections is possible [5,19,21,23]. 
Patients with NF-MPNST undergo both imaging studies and
operations more frequently, relative to those with sMPNSTs,
in an attempt by clinicians and patients to achieve an early
diagnosis and resection, and overcome the challenges in dis-
tinguishing MPNSTs from benign neurofibromas [6,12,26].
All of these differences could burden both the patients with
NF-1 and clinicians during the process of MPNST manage-
ment [6,12,19-21]. These changes in modern management
patterns might have reduced the previously mentioned sur-
vival difference between sMPNST and NF-MPNST [5,12].
Therefore, the role of these management strategies should be
investigated prospectively [20].
The increased identification of genetic cancers in recent
years has led to the development of agents that target genetic
alterations [27,28]. NF1 acts as a tumor suppressor; hence, the
genetic alteration of NF1 is among the etiologies of MPNST
in patients with NF-1 [8]. On the other hand, other genetic
abnormalities contribute to the malignant transformation of
benign neurofibromas [29,30]. Given the previously men-
tioned clinical characteristics, the management of NF-MPN-
ST requires the development of specific clinical prevention
methods and molecular targeting agents [22,30].
The present study had some unique points, such as a rela-
tive large single-institution cohort and a focus on Asian eth-
nicity. On the other hand, this study was retrospective, and
the gradual changes in treatment modalities and intensities
over the long study period need to be acknowledged.
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Table 2. Multivariate analysis of the overall survival of patients with localized malignant peripheral nerve sheath tumors
Variable Hazard ratio 95% CI p-value
Age
! 45 yr vs. < 45 yr 0.81 0.38-1.70 0.571
NF-1 vs. sporadic 1.18 0.48-2.90 0.716
Margin
R0 1.00 (reference)
R1 1.47 0.54-3.98 0.449
R2 2.61 1.03-6.61 0.043
Tumor size
! 5 cm vs. < 5 cm 1.040 0.40-2.68 0.935
Histologic grade
G1 0.18 0.05-0.71 0.014
G2 1.19 0.50-2.82 0.699
G3 1.00 (reference)
CI, confidence interval; NF-1, neurofibromatosis type 1.
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Conclusion
MPNSTs associated with NF-1 tend to arise at a younger
age, are generally larger, and are diagnosed at a higher stage
compared to sMPNST. In addition, NF-MPNST and sMPNST
have different diagnostic and treatment patterns. These 
results highlight the need for further investigation of specific
strategies that account for the differences in clinical and 
genetic backgrounds.
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